DCM
PACB icon

Difesa Capital Management’s Pacific Biosciences PACB Stock Holding History

Difesa Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-36,700
Closed -$488K – 21
2023
Q2 		$488K Buy
+36,700
New +$446K 1.28% 18
2022
Q4 		– Sell
-12,000
Closed -$70K – 250
2022
Q3 		$70K Buy
+12,000
New +$68.8K 0.04% 115

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Difesa Capital Management's PACB Position: Q3 2023 in Review

Difesa Capital Management sold out of Pacific Biosciences (PACB) in Q3 2023, closing a stake of 36,700 shares — an estimated $488K sold.

Difesa Capital Management first reported a position in PACB in Q3 2022 and held it in 2 quarters. The position peaked at $488K in Q2 2023. 274 funds tracked by Wall St. Rank hold PACB as of Q3 2023.

  • Difesa Capital Management reported no remaining Pacific Biosciences position as of Q3 2023 after selling out during the quarter.
  • Difesa Capital Management sold 36,700 Pacific Biosciences shares in Q3 2023, an estimated $488K.
  • Difesa Capital Management first reported a position in Pacific Biosciences in Q3 2022 and held it in 2 quarters.
  • Difesa Capital Management's Pacific Biosciences position peaked at $488K in Q2 2023.
  • 274 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2023.

Based on Difesa Capital Management's 13F filing for Q3 2023.